Lab 21 have announced that that a test of its MycAssay Aspergillus has been successful in detecting IA in a mixed population of 159 patients which had underlying haematological or critical illness.
IA is seen in patients who are immunocompromised which results in some organs being less well protected by the immune system, as the blood supply to them is not as rich. This is usually a hidden, silent disease and early detection could result in greatly improved patient outcomes.
Berwyn Clarke, CSO at Lab21 said: “The results of this evaluation confirm that our new CE-marked assay for the diagnosis of IA represents a first-in-class addition to fungal diagnostics enabling faster, more reliable and sensitive case detection. We are in the process of conducting additional studies to firmly establish its clinical utility in high-risk settings.”
This is great news as current tests often give false-positive or false-negative results. This new data will hopefully be introduced into routine fungal disease guidelines as soon as possible.